Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223958 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
A Phase 3 study of Neovascular Age-related Macular Degeneration, sponsored by Ocular Therapeutix.
- Active
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
- 20
- Study locations
NCT06223958: Active Phase 3 study of Neovascular Age-related Macular Degeneration, sponsored by Ocular Therapeutix.
NCT06223958 is a Phase 3 study of Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by Ocular Therapeutix. The registered enrollment target is 344 participants, below the 398-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06223958, a Phase 3 study of Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Ocular Therapeutix.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Primary Outcome
Maintenance of visual acuity, defined as \< 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters Best corrected visual acuity (BCVA) loss
Conditions Studied
Interventions
- DRUG Aflibercept
- DRUG OTX-TKI (axitinib implant)
Study Locations (20)
California
- CA CRC California Retina Consultants - Bakersfield
- The Retina Partners - Encino - Encino
- Retina Consultants of Orange County - Fullerton - Fullerton
- Atlantis Eyecare - Huntington Beach
- Lakeside Vision Center - Irvine - Irvine
- Retina-Vitreous Associates Medical Group - Los Angeles - Los Angeles
- CA RCMG Retinal Consultants Medical Group, Inc. - Modesto
- Retina Sacramento MSO, LLC - Modesto
- Kaiser Permanente Division of Research - Oakland
- CA CRC California Retina Consultants - Oxnard
- Stanford University School of Medicine, Byers Eye Institute - Palo Alto
- Doheny Eye Center - Pasadena
- AzulVision - Pasadena
- Orange County Retina Medical Group - Santa Ana
- California Retina Consultants (CRC) - Santa Barbara - Santa Barbara
- Macula Retina Vitreous Center - Torrance
Arizona
- Associated Retina Consultants - Gilbert - Gilbert
- Associated Retina Consultants - Phoenix - Phoenix
- Retinal Research Institute - Phoenix
- Retina Macula Institute of Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2027-09-27 |
| Phase | Phase 3 |
What the registry record for NCT06223958 still lists
NCT06223958 is an interventional study that assigns participants to a tested intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap, below the 398-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Aflibercept is the first listed.
NCT06223958 names 20 study sites across 2 states, led by California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06223958 about?
NCT06223958 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration". Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
What is the current status of trial NCT06223958?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2024-01-29. Estimated completion is 2027-09-27.
What conditions does trial NCT06223958 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT06223958?
The interventions under investigation include: Aflibercept (DRUG), OTX-TKI (axitinib implant) (DRUG).
Who is sponsoring clinical trial NCT06223958?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06223958 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06223958's enrollment target sits among peer trials
344 10th of 33 higher than 24 of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Extension Study for the Port Delivery System With Ranibizumab (Portal)
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI